IND-Enabling Development of a Small Molecule COVID Therapeutic
Document text
Principal Investigator: Ryan P Bennett Organization: OYAGEN, INC. Fiscal Year: 2024 Award: $300,000 Funding agency: National Institute of Allergy and Infectious Diseases The proposed Phase I SBIR will conduct IND-enabling studies to establish the pharmacokinetics (PK) and SARS-CoV-2 (CoV-2) antiviral efficacy of sangivamycin (Sang) in Golden Syrian hamsters. Sang is an adenosine nucleoside analog that we discovered to be a potent, dose- dependent inhibitor of CoV-2 during in vitro viral infectivity studies conducted at the NIAID- Integrated Research Facility (IRF) at Fort Detrick. Sang had significantly superior efficacy against multiple variants of CoV-2 compared with Remdesivir but Sang also was additive with Remdesivir when used in combination. CoV-2 is the causative agent of COVID-19, which was first documented in China in December 2019 and has since rapidly spread across the globe, leading the World Health Organization to declare a global pandemic on March 11, 2020. CoV-2 has infected greater than 600 million individuals worldwide with at least 6.4 million attributable deaths to date. OyaGen has held type B preIND meetings with the FDA (PIND 150794). Historically, Sang was safely tested in 88 human subjects during NCI cancer clinical trials but was abandoned due to its lack of efficacy against cancers in human subjects. In this Phase I SBIR OyaGen seeks to complete preclinical development of Sang as a therapeutic candidate for COVID-19 to facilitate an IND application to conduct appropriate clinical trials leading to regulatory approval and commercialization. In response to FDA guidance and comments to our preIND filing (150794) the goal of this proposal is to conduct PK of Sang in a hamster animal model (Aim 1) as well as to determine in vivo antiviral efficacy of Sang in the hamster COVID-19 model (Aim 2). The development of Sang as a therapeutic for infected patients is a medical countermeasure for immunocompromised people who may not benefit from immunization as well as a stop gap therapeutic for new strains of CoV for which current vaccines may be less effective. Importantly, our data support that Sang has the potential to enhance the efficacy of other therapeutics as a combination therapy option in the future. Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><Acute><Adenosine><Agreement><Animal Model><Animal Models and Related Studies><Animals><Anti-viral Agents><Blood Serum><Body Tissues><Body Weight decreased><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 anti-viral><COVID-19 antiviral><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 pandemic><COVID-19 period><COVID-19 public health crisis><COVID-19 therapeutics><COVID-19 therapy><COVID-19 treatment><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID-19 virus infection><COVID-19 years><COVID19 infection><COVID19 virus><CV-19><Cancers><Canine Species><Canis familiaris><Cats><Cats Mammals><Caymans><Cell Body><Cells><Chemicals><Chickens><China><Clinic><Clinical><Clinical Trials><CoV-2><CoV2><Combined Modality Therapy><Comment><Commentary><Control Animal><Coronaviridae><Coronavirus><Coronavirus Infectious Disease 2019><Cricetinae><Data><Development><Dogs><Dogs Mammals><Domestic Cats><Dose><Drops><Drug Kinetics><Drug resistance><Ducks><Early-Stage Clinical Trials><Editorial Comment><Enzyme Gene><Enzymes><Evaluation><FDA approved><Family suidae><Feline Species><Felis catus><Felis domestica><Felis domesticus><Felis sylvestris catus><Ferrets><Formulation><Funding><Future><GS-5734><Gallus domesticus><Gallus gallus><Gallus gallus domesticus><Goals><Golden Hamsters><Golden Syrian Hamsters><Guide RNA><H3 radionuclide><Half-Life><Hamsters><Hamsters Mammals><Hour><Human><Immunization><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunosuppressed Host><In Vitro><Individual><Infection><Inflammatory Response><Intravenous><Label><Legal patent><Licensing><Lower respiratory tract structure><Lung><Lung Inflammation><Lung Respiratory System><Macaca><Macaque><Mainland China><Malignant Neoplasms><Malignant Tumor><Maximal Tolerated Dose><Maximally Tolerated Dose><Maximum Tolerated Dose><Mesocricetus auratus><Mice><Mice Mammals><Modeling><Modern Man><Multimodal Therapy><Multimodal Treatment><Murine><Mus><NIAID><Nasal cavity><National Institute of Allergy and Infectious Disease><Non-Polyadenylated RNA><Outcome><Ownership><Patents><Patients><Persons><Pharmaceutical Agent><Pharmaceuticals><Pharmacokinetics><Pharmacologic Substance><Pharmacological Substance><Phase><Phase 1 Clinical Trials><Phase I Clinical Trials><Phosphorylation><Pigs><Pneumonitis><Protein Phosphorylation><Published Comment><Pulmonary Inflammation><RNA><RNA Gene Products><Recommendation><Recovery><Regimen><Research><Ribonucleic Acid><SARS><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS coronavirus disease><SARS-Associated Coronavirus><SARS-CO-V2><SARS-COVID-2><SARS-CoV><SARS-CoV disease><SARS-CoV-1><SARS-CoV-2><SARS-CoV-2 anti-viral><SARS-CoV-2 antiviral><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 inhibitor><SARS-CoV-2 pandemic><SARS-CoV-2 therapeutics><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 anti-viral><SARS-CoV2 antiviral><SARS-CoV2 infection><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 therapeutics><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><SBIR><Safety><Serum><Severe Acute Respiratory Coronavirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome coronavirus disease><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 inhibitor><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 therapeutics><Severe acute respiratory syndrome related corona virus 2><Small Business Innovation Research><Small Business Innovation Research Grant><Suidae><Swine><Syrian Hamsters><Technology><Testing><Texas><Therapeutic><Tissues><Tritium><Upper respiratory tract><Vaccines><Variant><Variation><Veklury><Viewpoint><Viral><Viral Burden><Viral Load><Viral Load result><Viremia><Weight Loss><Weight Reduction><World Health Organization><Wuhan coronavirus><animal safety><anti-cancer therapeutic><anti-viral compound><anti-viral drugs><anti-viral efficacy><anti-viral medication><anti-viral therapeutic><anti-virals><attributable death><attributable mortality><block SARS-CoV-2><block severe acute respiratory syndrome coronavirus 2><body weight loss><cancer clinical trial><canine><chemical synthesis><combat><combination therapy><combined modality treatment><combined treatment><commercialization><compare to control><comparison control><corona virus><coronavirus disease 2019><coronavirus disease 2019 anti-viral><coronavirus disease 2019 antiviral><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 therapeutics><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 virus><coronavirus infectious disease-19><design><designing><developmental><domestic dog><drug resistant><effective therapy><effective treatment><fighting><gRNA><hCoV19><healthy volunteer><human subject><immunosuppressed patient><in vivo><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><inhibit SARS-CoV-2><inhibit severe acute respiratory syndrome coronavirus 2><intravenous injection><lower respiratory tract><malignancy><medical countermeasure><meeting><meetings><model of animal><multi-modal therapy><multi-modal treatment><nCoV2><neoplasm/cancer><nucleoside analog><oncology clinical trial><pandemic><pandemic disease><pharmaceutical><phase I protocol><porcine><pre-clinical development><pre-clinical study><preclinical development><preclinical study><programs><pulmonary><radioactive hydrogen><remdesivir><research facility><resistance strain><resistance to Drug><resistant strain><resistant to Drug><response><sangivamycin><severe acute respiratory syndrome coronavirus 2 anti-viral><severe acute respiratory syndrome coronavirus 2 antiviral><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe acute respiratory syndrome-CoV><small molecule><suid><therapeutic candidate><therapeutics against COVID-19><therapeutics against SARS-CoV-2><therapeutics against SARS-coronavirus-2><therapeutics against Severe acute respiratory syndrome coronavirus 2><therapeutics against coronavirus disease 2019><therapeutics for novel coronavirus><timeline><treat COVID-19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><upper airway tract><viraemia><viral RNA><viral sepsis><virus RNA><virusemia><wt-loss>